Intravitreal ranibizumab injection for choroidal neovascularization in Strümpell-Lorrain Syndrome.

Abstract

Strümpell-Lorrain syndrome, or hereditary spastic paraplegia is a genetic disease of the central nervous system affecting the spinal cord and cerebellum. It represents a clinically heterogenous group of neurodegenerative disorders characterized by progressive spasticity and hyperreflexia of the lower limbs. Ocular abnormalities include keratitis, macular pigmentary abnormalities, juxtafoveolar retinal telangiectasis and choroidal neovascularization. We report the first case of choroidal neovascularization associated with Strüpell-Lorrain syndrome treated successfully with intravitreal ranibizumab injection.

• Authors: T H C Tran, G Baglin, G Querques
• Journal: Journal francais d'ophtalmologie (J Fr Ophtalmol) Vol. 35 Issue 5 Pg. 353-5 (May 2012) ISSN: 1773-0597 [Electronic] France
• PMID: 22463854 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Ranibizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Choroidal Neovascularization (drug therapy, genetics)
• Female
• Humans
• Intravitreal Injections
• Ranibizumab
• Spastic Paraplegia, Hereditary (complications)
• Young Adult